Posts Tagged 'PharmaCyte'

Written by Ι Stock Market Media — February 4, 2019

Clinical stage biotechnology company PharmaCyte Biotech (OTCQB: PMCB) is now closer than ever to reaching what would be a monumental milestone in the company’s history. Years of patience from PharmaCyte’s shareholders has now likely been whittled down to what should now be just months, and with the condensed timeline, the company is this close to what will be a landmark event—an “open” or approved Investigational New Drug application (IND) with the U.S. ...

Written by Ι Stock Market Media — January 23, 2019

“I am excited about this new approach that has the potential to change the way solid tumors are treated far beyond tumors in the pancreas.”

NEW YORK, NY – With PharmaCyte Biotech, Inc.’s (OTCQB: PMCB) naming of Medpace, Inc., a global full-service clinical contract research organization (CRO) to conduct its clinical trial in locally advanced, inoperable pancreatic cancer (LAPC), and with the recent news that the live cells necessary for that clinical trial ...

Written by Ι Stock Market Media — June 6, 2018

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world, the U.S. Food and Drug Administration (FDA).  It would be the company’s first clinical trial ever and could serve as the event that changes the way solid cancerous tumors are treated, ...

SILVER SPRING, Md., Dec. 15, 2015 (GLOBE NEWSWIRE) — PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted treatments for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, announced today that it has released a new video that highlights PharmaCyte’s diabetes treatment development program. PharmaCyte invited Stock Market Media Group to sit in on its 2nd Annual International Diabetes Consortium in Vienna, Austria, to document PharmaCyte’s story related to the development of its treatment ...

Written by Ι Stock Market Media — May 20, 2015

PharmaCyte Biotech (OTCQB: PMCB) has managed to do something that is rarely done in science – bring together an international group of leading experts to work on one project. The project that is drawing their interest is PharmaCyte Biotech’s diabetes treatment and getting it into the hands of insulin-dependent patients around the world. These experts have become known collectively as the “International Diabetes Consortium,” and if PharmaCyte is to be successful, it will ...